Related Experiment Video
Updated: Aug 4, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Studies on tumor induced angiogenesis
J L Ambrus1, C M Ambrus, P Forgach
1Roswell Park Cancer Institute, State University of New York, Buffalo.
Abstract:
Methods were developed to test angiogenic response to human tumor implants and various biologic agents in the cornea of rabbits and non-human primates (Macaca arctoides). Crude PDGF preparations were found to have significant angiogenic effect. Purified, recombinant PDGF preparations were also effective inhibitors (e.g. pentoxifylline (Px) (which also were found to release PgI2 and t-PA) inhibited human tumor implant induced angiogenesis and reduced spontaneous metastases in 3 transplantable murine tumors (Furth-Columbia Wilms' tumor in Furth-Wistar rats, C-1300 neuroblastoma in A/J mice and HM-Kim mammary carcinoma in Wistar rats) but not in the NIH adenocarcinoma in Balb/c mice. Sodium diethyldithiocarbamate (DDTC), a metal complexing agent with special affinity to copper and anti-thyroid as well as, immune stimulating activity was shown to be anti-angiogenic and to potentiate the effect of Px. The anti-fibrinolytic agents epsilon amino caproic acid (EACA) and tranaxamic acid (t-AMCHA) were anti-angiogenic. DDTC and Px were synergistic from this point of view.
Insights
This study explored angiogenesis inhibitors, finding pentoxifylline (Px) and sodium diethyldithiocarbamate (DDTC) reduced tumor growth and metastasis in animal models. These agents show promise for anti-angiogenic cancer therapy.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Platelet-derived growth factor (PDGF) plays a role in angiogenesis.
- Developing effective anti-angiogenic therapies is a key goal in cancer treatment.
Purpose of the Study:
- To evaluate the anti-angiogenic potential of various biologic agents.
- To investigate the efficacy of pentoxifylline (Px) and sodium diethyldithiocarbamate (DDTC) in inhibiting tumor-induced angiogenesis and metastasis.
- To explore synergistic effects between anti-angiogenic agents.
Main Methods:
- Development of methods to test angiogenic response in rabbit and non-human primate corneas.
- Administration of crude and purified PDGF preparations.
- Testing of pentoxifylline (Px), sodium diethyldithiocarbamate (DDTC), epsilon amino caproic acid (EACA), and tranaxamic acid (t-AMCHA) in various murine tumor models.
- Assessment of tumor implant-induced angiogenesis and spontaneous metastases.
Main Results:
- Crude PDGF demonstrated angiogenic effects.
- Purified PDGF also showed angiogenic properties.
- Pentoxifylline (Px) inhibited tumor-induced angiogenesis and reduced spontaneous metastases in three out of four tested murine tumors.
- Sodium diethyldithiocarbamate (DDTC) exhibited anti-angiogenic activity and potentiated the effect of Px.
- Anti-fibrinolytic agents EACA and t-AMCHA were also anti-angiogenic.
- DDTC and Px showed synergistic anti-angiogenic effects.
Conclusions:
- Pentoxifylline (Px) and sodium diethyldithiocarbamate (DDTC) are effective inhibitors of tumor angiogenesis and metastasis in specific preclinical models.
- DDTC potentiates the anti-angiogenic effects of Px, suggesting potential for combination therapy.
- Further research into these agents could lead to novel anti-angiogenic cancer treatments.
Related Concept Videos
The Tumor Microenvironment
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply

